Bristol-Myers Squibb Company (BMY)

NYQ – Real vaqt narxi. Valyuta: USD

57.52

+2.13 (3.85%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

57.40

-0.12 (-0.21%)

Bozordan keyin: Jun 26, 2026, 8:00 PM EDT

16.06.2026

Can BMY's Camzyos Strengthen Its Cardiovascular Portfolio?

Bristol Myers eyes growth from Camzyos as the FDA reviews its use in adolescents with obstructive HCM, expanding the drug's market reach.

16.06.2026

3 Dividend Stocks to Hold for the Long Haul

These three healthcare leaders are slowly overcoming recent obstacles. They have strong dividend track records and the means to maintain healthy dividend growth.

15.06.2026

A Dramatic Shift in Fed Policy Just Unlocked a New Era for Bristol Myers Squibb

With the 10-Year Treasury yielding 4.48% and the Fed signaling more cuts ahead, income investors are hunting for yield that compounds.

13.06.2026

How Safe is Bristol Myers Squibb's Dividend? Here's My Honest Take.

Bristol Myers Squibb's yield is well above the pharma average, and it has patent expirations on the horizon. The payout ratio isn't outlandishly high, and the company is financially strong, as it deals with pretty normal issues in the drug sector.

12.06.2026

Can Bristol Myers' Growth Portfolio Offset Legacy Drug Declines?

BMY's growth portfolio now drives more than half of revenues, with strong gains from Reblozyl, Breyanzi and Cobenfy helping offset legacy drug declines.

11.06.2026

Why Bristol Myers Squibb (BMY) Outpaced the Stock Market Today

Bristol Myers Squibb (BMY) closed at $56.87 in the latest trading session, marking a +2.28% move from the prior day.

11.06.2026

Bristol Myers Squibb Dividend Raise Streak is 18 Years. Here's 1 Number That Says the Streak Will Continue.

Multiple patent cliffs raise concerns about whether Bristol Myers Squibb can maintain its dividend growth streak. $3.5 billion in anticipated annual cost savings could help the pharmaceutical company bolster its quarterly payouts.

Videolar

06.02.2026

Positive

Bristol Myers Squibb CEO: Richest product pipeline we've had in the last decade

21.01.2026

Neutral

Final Trade: BMY, IGV, SOXX, GEN, AMZN

20.01.2026

Positive

2 Top Blue-Chip Stocks to Buy and Hold in 2026

23.12.2025

Neutral

Jenny Harrington's top dividend plays for 2026

Reytinglar oshishi / pasayishi

Ticker	Tashkilot	Reyting o‘zgarishi	Maqsadli narx	Sana
BMY	Cantor Fitzgerald	Neutral	undefined >> $55	April 22nd 2025
BMY	Piper Sandler	Overweight	undefined >> undefined	April 22nd 2025
BMY	Jefferies	Buy	undefined >> $70	December 16th 2024

Press-relizlar

08.06.2026

Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMY--Mariska Hargitay Partners with BMS for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease.

03.06.2026

Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”). Under the agreement, Arcus will supply casdatifan, the company's investigational small-molecule HIF-2a inhibitor, to be eval.

02.06.2026

Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma

REDMOND, Wash. & PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival.

01.06.2026

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CAMZYOS--US FDA Accepts for Priority Review Bristol Myers Squibb's Supplemental New Drug Application for Camzyos to Treat Adolescents with oHCM.

Bristol-Myers Squibb Company (BMY)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Bristol-Myers Squibb Company (BMY)

Can BMY's Camzyos Strengthen Its Cardiovascular Portfolio?

3 Dividend Stocks to Hold for the Long Haul

A Dramatic Shift in Fed Policy Just Unlocked a New Era for Bristol Myers Squibb

How Safe is Bristol Myers Squibb's Dividend? Here's My Honest Take.

Can Bristol Myers' Growth Portfolio Offset Legacy Drug Declines?

Why Bristol Myers Squibb (BMY) Outpaced the Stock Market Today